Evidence map›Paper›PMID 33321356›Full record

ArticleMultiple sclerosis and related disorders2021

Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.

Louise Rath, Minh Viet Bui, Julian Ellis, John Carey, Josephine Baker, Lisa Taylor, Hasini Fernando, Nicola Taylor, Poppy Savage, Janene Richards and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Louise RathAlfred Health, Clinical Neurosciences, Melbourne, Australia. Electronic address: l.rath@alfred.org.au.
Minh Viet BuiAlfred Health, Clinical Neurosciences, Melbourne, Australia.
Julian EllisAlfred Health, Clinical Neurosciences, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne Australia.
John CareyRoyal Melbourne Hospital, Melbourne, Australia.
Josephine BakerRoyal Melbourne Hospital, Melbourne, Australia.
Lisa TaylorRoyal Melbourne Hospital, Melbourne, Australia.
Hasini FernandoRoyal Melbourne Hospital, Melbourne, Australia.
Nicola TaylorRoyal Melbourne Hospital, Melbourne, Australia.
Poppy SavageRoyal Melbourne Hospital, Melbourne, Australia.
Janene RichardsAlfred Health, Clinical Neurosciences, Melbourne, Australia.
Michael ZhongAlfred Health, Clinical Neurosciences, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne Australia.
Tomas KalincikRoyal Melbourne Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
Olga SkibinaAlfred Health, Clinical Neurosciences, Melbourne, Australia.
Robb WesselinghAlfred Health, Clinical Neurosciences, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne Australia.
Ai-Lan NguyenRoyal Melbourne Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
Mastura MonifAlfred Health, Clinical Neurosciences, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne Australia.
Helmut ButzkuevenAlfred Health, Clinical Neurosciences, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne Australia.
Anneke van der WaltAlfred Health, Clinical Neurosciences, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne Australia.
Alfred Health · AUThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients.

objectiveTo analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic.

methodsPatients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed.

resultsWe analysed 269 rapid natalizumab infusions and 100 rapid ocrelizumab infusions. Infusion related reactions during the natalizumab or ocrelizumab infusions occurred in two patients (1.52%) and eight patients (8%), respectively. All infusion related reactions were mild to moderate and did not require infusion discontinuation. No infusion reactions occurred during the post-infusion observation. Patient experience was positive.

conclusionFrequency or severity of infusion related reactions in rapid infusions were no different compared to published data. In the setting of COVID-19, pandemic rapid infusion protocols could potentially save hospital resources and limit patient exposure to a high-risk clinical setting while still maintaining ongoing treatment of multiple sclerosis.

Indexed as

COVID-19AdultAntibodies, Monoclonal, HumanizedFemaleHumansImmunologic FactorsInfusions, IntravenousMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingNatalizumabSARS-CoV-2Antibodies, Monoclonal, HumanizedImmunologic FactorsNatalizumabocrelizumabCOVID-19 pandemicinfusion related reactionsMultiple Sclerosisnatalizumabocrelizumabpost observational timerapid infusionsresource utilisation

Identifiers

PMID33321356
PMCPMC7955770
OpenAlexW3107305002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.